News

Phase 1/2 EdiTHAL trial data shows reni-cell remained well-tolerated and displayed promising efficacy for patients with TDT.

An analysis of real-world data from propensity score-matched pairs of breast cancer patients treated with anthracyclines suggests statin use was associated with an 18% reduction in all-cause mortality.

These data, presented at RAD 2024, highlight the potential of delgocitinib cream for patients with chronic hand eczema in terms of patient and clinician reported outcomes.

Lower free thyroxine levels were linked to worse renal outcomes in patients with IgAN, and free thyroxine with tubular atrophy/interstitial fibrosis had high predictive value for IgAN prognosis.

A review of nearly 500 studies spanning more than 30 years details associations between weather events and cardiovascular risk.

Despite missing the primary endpoint among the global study population, additional analyses of participants from the US revealed significant impacts on mortality reduction with larsucosterol.

Patients in the spesolimab cohort demonstrated rapid improvements in DLQI scores compared with placebo, which were maintained through week 48.

Phase 1/2/3 trial data show the investigational gene-editing medicine has been well-tolerated, with encouraging efficacy, for people living with SCD.

Check out the first in our series of quizzes testing your knowledge the ESC/EAS 2019 guidelines on dyslipidemia. this quiz focuses on basic lipid management principles!

The FDA provided 510(k) clearance for the COR-12 wireless ECG device, which was now integrated with the SpiroSphere.

Survey results called attention to gaps in physicians’ clinical knowledge of IgAN, with incorrect responses prevalent among both specialists and generalists.

These data highlighted which drug, in combination with topical corticosteroids, produced the best efficacy results for those with atopic dermatitis.

Matthew Zirwas, MD, reviews the clinical discrepancies of certain JAK-targeting therapies and their role in dermatology patient outcomes.

Based on the 36-item Short Form Survey questionnaire, adults with SCD in France report low physical and mental health summary scores.

Matthew Zirwas, MD, discusses the prospect of pairing JAK inhibitors like ruxolitinib cream with other disease-targeting options for conditions including vitiligo and alopecia areata.

These data, presented at RAD 2024, highlight the potential benefits of upadacitinib for adults and adolescents observed in the Measure Up 1 and Measure Up 2 studies.

After a biosimilar introduction, the prices of the biologic products—namely, trastuzumab, infliximab, bevacizumab, adalimumab, filgrastim, and pegfilgrastim—were significantly reduced.

Responses were highly durable throughout 4 years of bimekizumab treatment.

Jennifer L. Hsiao, MD, reviews the rapidly growing inventory of investigational drugs for HS.

This approval by FDA officials allows patients an alternative option to pre-filled syringe, which had been the only choice for those with eczema prescribed tralokinumab.

New research reveals that elevated lipoprotein(a) and oxidized phospholipids are independent risk factors for early-stage heart failure progression.

Matthew Zirwas, MD, explains why he believes agents like ruxolitinib cream and upadacitinib have become the optimal treatments for atopic dermatitis, hidradenitis suppurativa, and more.

Hydroxyurea treatment may impact seminal fluid levels and ovarian reserves in male and female patients with sickle cell disease.

Significantly greater improvements were reported at week 2, which were sustained through week 12, in patients receiving the halobetasol propionate/tazarotene lotion compared with the vehicle cohort.

Sidbury covered the similarities and differences between the new guideline updates by the AAD on atopic dermatitis as well as differences with other organizations’ guidelines.

In new late-breaking data, alopecia patients’ real-world incidence of atopic dermatitis was highlighted by investigators.

Findings from a pair of phase 2a trials showed combination imdusiran and IFN or VTP-300 with standard-of-care NA therapy led to meaningful and sustained reductions in HBsAg levels.

Overall, 189 (74.1%) patients treated with brodalumab achieved PASI 75, 133 (52.2%) achieved PASI 90, and 98 (38.4%) achieved PASI 100.